Sohn, whose resignation was effective March 31, was still listed on Imaging3’s website today. The company agreed to pay out $9,100 in severance, according to the filing.
Biolase Technology (NSDQ:BLTI) CEO Federico Pignatelli agreed to another year at a $1 salary as the dental laser maker met Wall Street’s 4th-quarter forecast with a whopping 35% top-line bump.
Pignatelli set his annual pay package at $1 and 35,000 shares of BLTI stock when he took the role of vice chairman in July 2010, a month after he was terminated as president, SEC filings show.
The new slate of directors for Olympus Corp. (TYO:7733) is already drawing fire from foreign investors in the endoscopy giant, after its entire board resigned en masse over a $1.7 billion accounting scandal that’s slashed its valuation by about 50% since October.
Medtronic Inc. (NYSE:MDT) landed FDA clearance for its DF4 high-voltage right ventricular lead for use with implantable cardiac rhythm management devices.
The DF4, which builds on Medtronic’s Sprint Quattro lead, aims to help simplify the implantation process with a redesigned port and by providing visual confirmation of the lead’s connection to the device.
Medtronic (NYSE:MDT) won 510(k) clearance from the FDA for the Aquamantys surgical sealer it acquired when it paid $480 million for Salient Surgical Technologies last year.
AtriCure (NSDQ:ATRC) shares got a modest bump today after revealing pre-market approval from the FDA for its Synergy radiofrequency ablation system for atrial fibrillation.
ATRC shares were up 2.1% to $10.86 as of about 1 p.m. today.
Needle-free drug delivery company Bioject Medical Technologies (OTC:BJCT) announced the departure of its president & CEO "for cost-cutting reasons" on the heels of major cuts to its workforce.
Ralph Makar, who took the corner office at Bioject four years ago, ceded his role to board member Mark Logomasini, who will serve as interim president & CEO, effective immediately.
Volcano Corp. (NSDQ:VOLC) are down 4.4 percent this morning after the medical device company reported its third-quarter numbers yesterday, beating Wall Street’s expectations despite plunging profits, but lowering the top end of its sales guidance for the rest of the year.
The San Diego-based medical device maker posted profits of $2.6 million, or 5 cents per share, on sales of $85.8 million for the three months ended Sept. 30.